CClinicalTrials.gg
CompletedNCT06668168KETO-GENETICUpdated Jun 15, 2026

The Causal Role of Ketone Bodies in Obesity-associated Disease Prevention - Combining Genetic Epidemiology With a Randomised Trial to Infer Causality

An interventional study of Ketone Monoester (KE) and Ketogenic diet in Nutrition and Obesity and Overweight, sponsored by University of Bath. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University of Bath · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Excess weight increases the risk of several diseases including cardiovascular disease, type 2 diabetes, kidney disease and various cancers. There is a need for preventative strategies for obesity-associated disease, especially for people in the overweight and moderately obese ranges where pharmacological intervention may not be suitable.

Low-carbohydrate (ketogenic) diets are popular for weight control. Ketogenic diets increase circulating ketones, which can have favourable effects on cardiometabolic health markers. However, the ketogenic diet has a nutrient composition associated with harms (high-saturated fat/red meat, and low-fibre). The net effects of ketogenic diets on long-term health are unclear. Ketone supplements can increase circulating ketones and could provide benefits of ketosis without needing to adhere to a potentially harmful diet.

Establishing causality between complex exposures (e.g., diet) and long-term outcomes (e.g., disease), is challenging. The MRC \& NIHR Review of Nutrition and Human Health Research (2017) highlighted an "overreliance (as opposed to reasonable reliance) on observational studies" as a key barrier to progression in the field of nutrition and health. Randomised controlled trials (RCTs) facilitate causal inference, but for long-term outcomes are expensive, time-consuming, and often suffer from waning adherence. Mendelian randomization (MR) can estimate causal effects subject to key assumptions. A challenge to these assumptions includes complex behavioural exposures (e.g., diet), which could be intercorrelated with causal factors.

Our proposal will address these limitations with a novel combination of study designs to establish causal effects of ketosis (via diet and supplementation) on obesity-associated disease risk in humans.

The investigators will combine a tightly controlled, short-term RCT, with MR to link short-term responses to long-term endpoints. The investigators will examine the circulating (blood) and tissue-specific (adipose) transcriptomic and proteomic responses in the fasted and postprandial state in response to our dietary interventions and translate these to MR by identifying single-nucleotide polymorphisms from genome wide association studies. This approach overcomes limitations of RCTs and MR, as adherence to diets will be confirmed with controlled feeding, and intermediate molecular traits as exposure for MR are less likely to be intercorrelated with causal traits.

02

Conditions studied

  • Nutrition
  • Obesity and Overweight

Keywords

  • Ketogenic diet
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 69 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Bath is the lead sponsor of 91 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Body mass index: 25-45 kg/m2
  • Waist circumference >93.9 (males) or >79.9 (females)

Exclusion criteria

Exclusion Criteria:

  • Glucose or lipid lowering medication
  • Diagnosis of cardiovascular disease, renal failure, liver disease or type 2 diabetes
  • Contraindications to a ketogenic diet (e.g., pancreatitis, liver failure, disorders of fat metabolism, primary carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine translocase deficiency, porphyrias, or pyruvate kinase deficiency)
  • Unable to understand English language
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • No intervention
    CONTROL
  • Active comparator
    KETONE ESTER

    Dietary Supplement: Ketone Monoester (KE)

  • Experimental
    KETOGENIC DIET

    Behavioral: Ketogenic diet

Interventions

  • Dietary supplementKetone Monoester (KE)

    25g ketone ester 3x/day. The ketone ester will be a beta-hydroxybutyrate monoester \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate\].

  • BehavioralKetogenic diet

    Ketogenic diet (\<50 g carbohydrate per day)

06

What researchers measure

Primary outcomes

  1. Plasma proteome

    Plasma proteome at week 4 adjusted for baseline values

    Time frame: From baseline to week 4

  2. Transcriptome of peripheral blood mononuclear cells

    Transcriptome of peripheral blood mononuclear cells at week 4 adjusting for baseline values

    Time frame: From baseline to week 4

  3. Transcriptome of adipose tissue

    Transcriptome of subcutaneous abdominal adipose tissue at week 4 adjusting for baseline values

    Time frame: From baseline to week 4

Secondary outcomes

  1. Apolipoprotein B concentrations

    Plasma apolipoprotein B concentrations at week 4 adjusted for baseline values.

    Time frame: From baseline to week 4

  2. Urinary albumin concentrations

    Urinary albumin concentrations at week 4 adjusting for baseline values

    Time frame: From baseline to week 4

  3. Fasting glucose concentrations

    Plasma fasting glucose concentrations at week 4 adjusting for baseline values

    Time frame: From baseline to week 4

07

Study locations

1 site
  • University of Bath
    Bath, BA2 7AY, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06668168
Lead sponsor
University of Bath
Collaborators
University of Bristol, Imperial College London
Responsible party
Javier Gonzalez (Professor of Nutrition and Metabolism, University of Bath) — Principal investigator
First posted
Oct 31, 2024
Start date
May 6, 2025
Primary completion
Jun 3, 2026
Completion
Jun 3, 2026
Last update
Jun 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion